Table 1.
Association between hepsin genomic alterations and metastasis in prostate cancer.
| Prostate Cancer without Metastasis | Prostate Cancer with Metastasis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total (%)-Mutation Types | Altered Numbers (%) | Non-Altered Numbers (%) | Sub-Total (%)-Mutation Types | Altered Numbers (%) | Non-Altered Numbers (%) | Sub-Total (%)-Mutation Types | Altered Numbers (%) | Non-Altered Numbers (%) | Odds Ratio (95% Confidence Interval) | p Value * |
| 7161 (100) | 44 (0.6) | 7117 (99.4) | 6082 (100) | 26 (0.4) | 6056 (99.6) | 1079 (100) | 18 (1.7) | 1061 (98.3) | 3.95 (2.15, 7.23) |
<0.0001 |
| Copy number alterations | Copy number alterations | Copy number alterations | ||||||||
| Amplification | 23 (52.3%) | Amplification | 10 (38.5%) | Amplification | 13 (72.2%) | 4.16 (1.13, 15.3) |
0.036 | |||
| Deletion | 8 (18.2%) | Deletion | 6 (23.1%) | Deletion | 2 (11.1%) | NS | ||||
| AAC | 13 (29.5%) | AAC | 10 (38.5%) | AAC | 3 (16.7%) | NS | ||||
| Sub-total | 44 (100%) | Sub-total | 26 (100%) | 18 (100%) | ||||||
Abbreviation: AAC, amino acid change. * Comparison between without metastasis and with metastasis groups. NS, not significant.